<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: incurred losses each year", fill: "#746cc0"},
{source: "4: incurred losses each year", target: "4: since inception", fill: "#746cc0"},
{source: "4: since inception", target: "4: accumulated deficit", fill: "#746cc0"},
{source: "4: incurred losses each year", target: "5: generated minimal revenues by licensing", fill: "#738678"},
{source: "5: generated minimal revenues by licensing", target: "5: technology", fill: "#738678"},
{source: "5: technology", target: "5: companies willing", fill: "#738678"},
{source: "5: companies willing", target: "5: development costs", fill: "#738678"},
{source: "5: generated minimal revenues by licensing", target: "6: technology may", fill: "#93c572"},
{source: "6: technology may", target: "6: widespread commercialization", fill: "#93c572"},
{source: "6: widespread commercialization", target: "6: several years", fill: "#93c572"},
{source: "6: technology may", target: "7: incur losses", fill: "#7b1113"},
{source: "7: incur losses", target: "7: several years", fill: "#7b1113"},
{source: "7: several years", target: "7: expenditures on research", fill: "#7b1113"},
{source: "7: expenditures on research", target: "7: development", fill: "#7b1113"},
{source: "7: development", target: "7: commercialization", fill: "#7b1113"},
{source: "7: commercialization", target: "7: administrative", fill: "#7b1113"},
{source: "7: administrative", target: "7: activities", fill: "#7b1113"},
{source: "7: activities", target: "7: significantly exceed", fill: "#7b1113"},
{source: "7: significantly exceed", target: "7: revenues during", fill: "#7b1113"},
{source: "7: incur losses", target: "12: future revenue", fill: "#e34234"},
{source: "12: future revenue", target: "12: profitability critically depend upon", fill: "#e34234"},
{source: "12: profitability critically depend upon", target: "12: successfully", fill: "#e34234"},
{source: "12: successfully", target: "12: senescence gene technology", fill: "#e34234"},
{source: "12: senescence gene technology", target: "12: technology", fill: "#e34234"},
{source: "12: technology", target: "12: later license", fill: "#e34234"},
{source: "12: later license", target: "12: market such", fill: "#e34234"},
{source: "12: future revenue", target: "29: connection with", fill: "#b06500"},
{source: "29: connection with", target: "29: securities than", fill: "#b06500"},
{source: "29: securities than", target: "29: certificate", fill: "#b06500"},
{source: "29: certificate", target: "29: incorporation currently authorizes", fill: "#b06500"},
{source: "29: incorporation currently authorizes", target: "29: common stock outstanding", fill: "#b06500"},
{source: "29: connection with", target: "31: Investors ", fill: "#08e8de"},
{source: "31: Investors ", target: "31: investment from future offerings", fill: "#08e8de"},
{source: "31: investment from future offerings", target: "31: common stock", fill: "#08e8de"},
{source: "31: Investors ", target: "72: enter into", fill: "#f8f4ff"},
{source: "72: enter into", target: "72: agreements with", fill: "#f8f4ff"},
{source: "72: agreements with", target: "72: consultants advisors", fill: "#f8f4ff"},
{source: "72: consultants advisors", target: "72: research collaborators", fill: "#f8f4ff"},
{source: "72: enter into", target: "143: certificate", fill: "#0047ab"},
{source: "143: certificate", target: "143: incorporation", fill: "#0047ab"},
{source: "143: incorporation", target: "143: bylaws could", fill: "#0047ab"},
{source: "143: bylaws could", target: "143: difficult", fill: "#0047ab"},
{source: "143: difficult", target: "143: third party", fill: "#0047ab"},
{source: "143: third party", target: "143: control would", fill: "#0047ab"},
{source: "143: control would", target: "143: beneficial", fill: "#0047ab"},
{source: "143: beneficial", target: "143: stockholders", fill: "#0047ab"},
{source: "143: certificate", target: "START_HERE", fill: "#0047ab"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Agricultural Products</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Equity_(finance)">Equity (finance)</a></td>
      <td>In finance, equity is ownership of assets that may have debts or other liabilities attached to them. Equity is measured for accounting purposes by subtracting liabilities from the value of the assets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. It is an emerging industry that uses technology to improve activities in finance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_company">Public company</a></td>
      <td>A public company, publicly traded company, publicly held company, publicly listed company, or public limited company is a company whose ownership is organized via shares of stock which are intended to be freely traded on a stock exchange or in over-the-counter markets. A public (publicly traded) company can be listed on a stock exchange (listed company), which facilitates the trade of shares, or not (unlisted public company).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Managed_Heart">The Managed Heart</a></td>
      <td>The Managed Heart: Commercialization of Human Feeling, by Arlie Russell Hochschild, was first published in 1983. A 20th Anniversary edition with a new afterword added by the author was published in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bioprospecting">Bioprospecting</a></td>
      <td>Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, aquaculture, bioremediation, cosmetics, nanotechnology, or pharmaceutical industries. In the pharmaceutical industry, for example,  almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.Terrestrial plants, fungi and actinobacteria have been the focus of many past bioprospecting programs, but interest is growing in less explored ecosystems (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholders'_agreement">Shareholders' agreement</a></td>
      <td>A shareholders' agreement (sometimes referred to in the U.S. as a stockholders' agreement) (SHA) is an agreement amongst the shareholders or members of a company. In practical effect, it is analogous to a partnership agreement.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholder">Shareholder</a></td>
      <td>A shareholder (in the United States often referred to as stockholder) of a corporation is an individual or legal entity (such as another corporation, a body politic, a trust or partnership) that is registered by the corporation as the legal owner of shares of the share capital of a public or private corporation. Shareholders may be referred to as members of a corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stockholder_of_record">Stockholder of record</a></td>
      <td>Stockholder of record is the name of an individual or entity shareholder that an issuer carries in its shareholder register as the registered holder (not necessarily the beneficial owner) of the issuer's securities. Dividends and other distributions are paid only to shareholders of record.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Jessica_Stockholder">Jessica Stockholder</a></td>
      <td>Jessica Stockholder (born 1959) is a Canadian-American artist known for site-specific installation works and sculptures that are often described as "paintings in space." She came to prominence in the early 1990s with monumental works that challenged boundaries between artwork and display environment as well as between pictorial and physical experience. Her art often presents a "barrage" of bold colors, textures and everyday objects, incorporating floors, walls and ceilings and sometimes spilling out of exhibition sites.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Derivative_suit">Derivative suit</a></td>
      <td>A shareholder derivative suit is a lawsuit brought by a shareholder on behalf of a corporation against a third party. Often, the third party is an insider of the corporation, such as an executive officer or director.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Friedman_doctrine">Friedman doctrine</a></td>
      <td>The Friedman doctrine, also called shareholder theory or stockholder theory, is a normative theory of business ethics advanced by economist Milton Friedman which holds that the social responsibility of business is to increase its profits. This shareholder primacy approach views shareholders as the economic engine of the organization and the only group to which the firm is socially responsible.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SENESCO TECHNOLOGIES INC      Item 1A            <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________       We have a limited operating history and have incurred substantial losses and     expect <font color="blue">future losses</font></td>
    </tr>
    <tr>
      <td>We are a <font color="blue"><font color="blue">development</font> stage bio<font color="blue">technology</font> company with</font> a limited operating     history and limited assets and capital</td>
    </tr>
    <tr>
      <td>We have <font color="blue">incurred losses each year</font>     <font color="blue">since inception</font> and have an <font color="blue">accumulated deficit</font> of dlra22cmam369cmam843 at June 30,     2006</td>
    </tr>
    <tr>
      <td>We have <font color="blue"><font color="blue">generated minimal revenues</font> by licensing</font> our <font color="blue">technology</font> for     certain  crops to <font color="blue"><font color="blue">companies will</font>ing</font> to share in our <font color="blue"><font color="blue">development</font> costs</font></td>
    </tr>
    <tr>
      <td>However, our <font color="blue">technology</font> may not be ready for <font color="blue">widespread <font color="blue">commercialization</font></font>     for  <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur losses</font> for the next     <font color="blue">several years</font> because we anticipate that our <font color="blue"><font color="blue">expenditures</font> on research</font> and     <font color="blue">development</font>,  <font color="blue">commercialization</font>  and  <font color="blue">administrative</font>  <font color="blue">activities</font>  will     <font color="blue"><font color="blue"><font color="blue">significant</font>ly</font> exceed</font> our <font color="blue">revenues during</font> that period</td>
    </tr>
    <tr>
      <td>In addition, we cannot     assure you that we will be able to sell our <font color="blue">New Jersey </font>state net operating     losses for any <font color="blue">specific fiscal year</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> when, if ever, we     <font color="blue">will become profitable</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> a single principal <font color="blue">technology</font> and, if our <font color="blue">technology</font> is not     <font color="blue"><font color="blue">commercially</font> successful</font>, we will have <font color="blue">no alternative source</font> of revenue</td>
    </tr>
    <tr>
      <td>Our primary business is the <font color="blue">development</font> and <font color="blue">commercial exploitation</font> of     <font color="blue">technology</font>  to identify, isolate, characterize and <font color="blue">silence genes which</font>     control the death of cells in humans and plants</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future revenue</font> and     <font color="blue">profitability critically depend upon</font> our ability to <font color="blue">successfully</font> develop     apoptosis and senescence gene <font color="blue">technology</font> and <font color="blue">later license</font> or <font color="blue">market such</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">conducted experiments on certain crops with</font> favorable     results  and  have  conducted certain preliminary cell-line and animal     experiments, which have <font color="blue">provided us with data upon which</font> we have designed     <font color="blue">additional research programs</font></td>
    </tr>
    <tr>
      <td>However, we <font color="blue">cannot give</font> any assurance that our     <font color="blue">technology</font> will be <font color="blue"><font color="blue">commercially</font> successful</font> or <font color="blue">economically viable</font> for any     crops or <font color="blue"><font color="blue">human health</font> <font color="blue"><font color="blue">application</font>s</font></font></td>
    </tr>
    <tr>
      <td>In addition, no assurance can be given that <font color="blue">adverse consequences might</font> not     result from the use of our <font color="blue">technology</font> such as the <font color="blue">development</font> of negative     <font color="blue">effects on humans</font> or plants or <font color="blue">reduced benefits</font> in terms of crop yield or     protection</td>
    </tr>
    <tr>
      <td>Our failure to obtain <font color="blue">market <font color="blue">acceptance</font></font> of our <font color="blue">technology</font> or to     <font color="blue">successfully</font> <font color="blue">commercialize</font> such <font color="blue">technology</font> or develop a <font color="blue"><font color="blue">commercially</font> viable</font>     <font color="blue">product would</font> have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>We outsource all of our research and <font color="blue">development</font> <font color="blue">activities</font> and, if we are     <font color="blue">unsuccessful</font> in maintaining our <font color="blue">alliances with</font> these <font color="blue">third parties</font>, our     research and <font color="blue">development</font> efforts may be delayed or curtailed</td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">third parties</font> to perform all of our research and <font color="blue">development</font>     <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">primary research</font> and <font color="blue">development</font> efforts take place at the     <font color="blue">University  </font>of  Waterloo  in Ontario, Canada, where our <font color="blue">technology</font> was     discovered, the University of Colorado, Mayo Clinic, the University of     Virginia, the University of Pittsburgh, and with our commercial partners</td>
    </tr>
    <tr>
      <td>At  this time, we do not have the <font color="blue">internal capabilities</font> to perform our     research and <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Accordingly, the failure of third-party     research partners, such as the University of Waterloo, to perform under     <font color="blue">agreements</font> entered into with us, or our failure to renew important research     <font color="blue">agreements</font> with these <font color="blue">third parties</font>, may delay or curtail our research and     <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________       We have <font color="blue"><font color="blue">significant</font> future capital</font> needs and may be unable to <font color="blue">raise capital</font>     when  needed, <font color="blue">which could force us</font> to delay or reduce our research and     <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td><font color="blue">As of June </font>30, 2006, we had cash and highly-liquid <font color="blue">investment</font>s valued at     dlra1cmam168cmam473 and working capital of dlra858cmam811</td>
    </tr>
    <tr>
      <td>In October 2006, we received     <font color="blue">aggregate net proceeds</font> of dlra2cmam050cmam000 from a <font color="blue">private placement</font> of our equity     securities</td>
    </tr>
    <tr>
      <td>Using our <font color="blue">available reserves as</font> of June 30, 2006, and the net     <font color="blue">proceeds from</font> the <font color="blue">private equity financing</font>, we believe that we can operate     <font color="blue">according</font> to our current business plan <font color="blue">at least through</font> June 30, 2007</td>
    </tr>
    <tr>
      <td>To     date, we have <font color="blue">generated minimal revenues</font> and anticipate that our operating     costs  will exceed any <font color="blue">revenues generated over</font> the next <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>Therefore, we will be required to <font color="blue">raise additional capital</font> in the future in     order to operate <font color="blue">according</font> to our current business plan, and this funding     may not be <font color="blue">available on</font> favorable terms, if at all</td>
    </tr>
    <tr>
      <td>If we are unable to     <font color="blue">raise additional funds</font>, we will need to do one or more of the following:       ·                   delay,  scale back or eliminate some or all of our     research and <font color="blue">development</font> programs;       ·                  license <font color="blue">third parties</font> to develop and <font color="blue">commercialize</font> our     <font color="blue">technology</font>  that  we <font color="blue">would otherwise seek</font> to develop and <font color="blue">commercialize</font>     ourselves;       ·                  <font color="blue">seek <font color="blue">strategic alliances</font></font> or business <font color="blue">combinations</font>, or     attempt to sell our company; or       ·                  <font color="blue">cease <font color="blue">operations</font></font></td>
    </tr>
    <tr>
      <td>In addition, in <font color="blue">connection with</font> any funding, if we need to issue more equity     <font color="blue">securities than</font> our <font color="blue">certificate</font> of <font color="blue"><font color="blue">in<font color="blue">corporation</font></font> currently <font color="blue">authorizes</font></font>, or     more than 20prca of the shares of our <font color="blue"><font color="blue">common stock</font> outstanding</font>, we may need     stockholder  approval</td>
    </tr>
    <tr>
      <td>If <font color="blue">stockholder approval</font> is not obtained or if     <font color="blue">adequate funds</font> are not available, we may be required to <font color="blue">curtail <font color="blue">operations</font></font>     <font color="blue"><font color="blue">significant</font>ly</font> or to obtain <font color="blue">funds through <font color="blue">arrangements</font> with collaborative</font>     partners or others that may require us to <font color="blue">relinquish rights</font> to certain of     our  <font color="blue">technologies</font>,  product candidates, products or <font color="blue">potential markets</font></td>
    </tr>
    <tr>
      <td><font color="blue">Investors </font>may experience dilution in their <font color="blue"><font color="blue">investment</font> from <font color="blue">future offerings</font></font>     of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>For example, if we <font color="blue">raise additional capital</font> by issuing     <font color="blue">equity securities</font>, such an <font color="blue">issuance would reduce</font> the <font color="blue">percentage ownership</font> of     <font color="blue">existing <font color="blue">stockholders</font></font></td>
    </tr>
    <tr>
      <td>In addition, assuming the exercise of all options     and warrants outstanding, as of June 30, 2006, we had 6cmam226cmam021 shares of     <font color="blue">common stock</font> authorized but unissued, which may be <font color="blue">issued from</font> time to time     by our board of <font color="blue">directors</font> without <font color="blue">stockholder approval</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font>     our <font color="blue">private placement</font> of <font color="blue">equity securities</font>, in October 2006, we issued an     aggregate of an additional 1cmam986cmam306 shares of <font color="blue">common stock</font> and warrants to     purchase 1cmam132cmam194 shares of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Therefore </font>assuming the exercise     of all options and <font color="blue">warrants granted as</font> of October 11, 2006, we had 3cmam107cmam521     shares of <font color="blue">common stock</font> authorized but unissued, which may be <font color="blue">issued from</font>     time  to  time by our board of <font color="blue">directors</font> without <font color="blue">stockholder approval</font></td>
    </tr>
    <tr>
      <td>Furthermore, we may need to <font color="blue">issue securities</font> that have rights, <font color="blue">preferences</font>     and <font color="blue">privileges senior</font> to our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Since our inception, we have financed all of our <font color="blue"><font color="blue">operations</font> through private</font>     equity  <font color="blue">financings</font></td>
    </tr>
    <tr>
      <td>Our future capital <font color="blue">requirements</font> <font color="blue">depend on</font> numerous     factors, including:       ·      the scope of our research and <font color="blue">development</font>;       ·                  our ability to attract business <font color="blue">partners willing</font> to share     in our <font color="blue"><font color="blue">development</font> costs</font>;       ·                  our ability to <font color="blue">successfully</font> <font color="blue">commercialize</font> our <font color="blue">technology</font>;       ·                  <font color="blue">competing technological</font> and market <font color="blue">development</font>s;       ·                  our ability to <font color="blue"><font color="blue">enter into</font> collaborative <font color="blue">arrangements</font></font> for     the  <font color="blue">development</font>,  <font color="blue">regulatory</font>  approval and <font color="blue">commercialization</font> of other     products; and       ·                  the cost of filing, prosecuting, defending and enforcing     patent claims and other <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________       Our  business  <font color="blue">depends upon</font> our patents and <font color="blue"><font color="blue">proprietary</font> rights</font> and the     <font color="blue">enforcement</font> of these rights</td>
    </tr>
    <tr>
      <td>Our failure to obtain and maintain patent     <font color="blue">protection may increase competition</font> and <font color="blue">reduce demand</font> for our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>As a result of the substantial length of time and <font color="blue">expense associated with</font>     developing  products  and  bringing  them  to  the  marketplace in the     bio<font color="blue">technology</font> and <font color="blue"><font color="blue">agricultural</font> industries</font>, obtaining and maintaining patent     and <font color="blue">trade secret protection</font> for <font color="blue">technologies</font>, products and processes is of     <font color="blue">vital importance</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part <font color="blue">on several factors</font>,     including, <font color="blue">without limitation</font>:       ·                   our  ability  to  obtain <font color="blue">patent protection</font> for our     <font color="blue">technologies</font> and processes;       ·                  our ability to preserve our <font color="blue">trade secrets</font>; and       ·                  our ability to operate <font color="blue">without infringing</font> the <font color="blue">proprietary</font>     rights of other <font color="blue">parties both</font> in the <font color="blue"><font color="blue">United States</font> </font>and in <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">been issued ten patents by</font> the US Patent and Trademark Office, or     PTO, and eight <font color="blue">patents from</font> <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">also filed numerous</font>     <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font> for our <font color="blue">technology</font> in the <font color="blue"><font color="blue">United States</font> </font>and in several     <font color="blue">foreign countries</font>, which <font color="blue">technology</font> is vital to our primary business, as     <font color="blue">well as several</font> <font color="blue">Continuations in Part </font>on these <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">success depends</font> in part upon the grant of <font color="blue">patents from</font> our <font color="blue">pending patent</font>     <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>Although we believe that our <font color="blue">technology</font> is unique and will not violate or     <font color="blue">infringe upon</font> the <font color="blue"><font color="blue">proprietary</font> rights</font> of any <font color="blue">third party</font>, we <font color="blue">cannot assure</font>     you that these claims will not be made or if made, could be <font color="blue">successfully</font>     <font color="blue">defended against</font></td>
    </tr>
    <tr>
      <td>If we do not obtain and maintain <font color="blue">patent protection</font>, we     <font color="blue">may face <font color="blue">increased competition</font></font> in the <font color="blue"><font color="blue">United States</font> </font>and <font color="blue">internationally</font>,     <font color="blue">which would</font> have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>Since <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font> in the <font color="blue"><font color="blue">United States</font> </font>are maintained in secrecy     until  patents are issued, and <font color="blue">since publication</font> of <font color="blue">discoveries</font> in the     scientific and <font color="blue">patent literature tend</font> to lag behind actual <font color="blue">discoveries</font> by     <font color="blue">several months</font>, we cannot be certain that we were the first creator of the     <font color="blue">inventions</font> <font color="blue">covered by</font> our pending <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font> or that we were the     first to file <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font> for these <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>In addition, among other things, we <font color="blue">cannot assure</font> you that:       ·      our <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font></font> will result in the issuance of patents;       ·      any <font color="blue">patents issued</font> or licensed to us will be <font color="blue">free from challenge</font> and     that if challenged, would be held to be valid;       ·                   any  <font color="blue">patents issued</font> or licensed to <font color="blue">us will provide</font>     <font color="blue">commercially</font>  <font color="blue">significant</font>  protection for our <font color="blue">technology</font>, products and     processes;       ·                   other  companies  will  not  <font color="blue">independently</font> develop     <font color="blue">substantially</font> equivalent <font color="blue">proprietary</font> information which is not <font color="blue">covered by</font> our     <font color="blue">patent rights</font>;       ·                  other <font color="blue">companies will</font> not obtain access to our know-how;       ·                  other <font color="blue">companies will</font> not be <font color="blue">granted patents</font> that may     prevent the <font color="blue">commercialization</font> of our <font color="blue">technology</font>; or       ·                   we  will  not require licensing and the payment of     <font color="blue">significant</font>  fees  or  royalties to <font color="blue">third parties</font> for the use of their     <font color="blue"><font color="blue">intellectual</font> property</font> in order to <font color="blue">enable us</font> to conduct our business</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________       Our <font color="blue"><font color="blue">competitors</font> may</font> allege that we are infringing upon their <font color="blue">intellectual</font>     <font color="blue">property rights</font>, forcing us to incur substantial costs and expenses in     resulting <font color="blue">litigation</font>, the outcome of <font color="blue">which would</font> be uncertain</td>
    </tr>
    <tr>
      <td>Patent law is <font color="blue">still evolving relative</font> to the scope and <font color="blue">enforceability</font> of     claims in the fields in which we operate</td>
    </tr>
    <tr>
      <td>We are like most bio<font color="blue">technology</font>     companies in that our <font color="blue">patent protection</font> is <font color="blue">highly uncertain</font> and involves     <font color="blue">complex legal</font> and <font color="blue">technical questions</font> for <font color="blue">which legal principles</font> are not yet     <font color="blue">firmly established</font></td>
    </tr>
    <tr>
      <td>In addition, if issued, our <font color="blue">patents may</font> not contain     claims <font color="blue">sufficiently broad</font> to protect us against <font color="blue">third parties</font> with similar     <font color="blue">technologies</font> or products, or <font color="blue">provide us with</font> any <font color="blue">competitive advantage</font></td>
    </tr>
    <tr>
      <td>The PTO and the courts have not established a <font color="blue">consistent policy</font> regarding     the breadth of claims allowed in bio<font color="blue">technology</font> patents</td>
    </tr>
    <tr>
      <td>The allowance of     broader claims may increase the incidence and cost of <font color="blue">patent interference</font>     <font color="blue">proceedings</font> and the risk of infringement <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>On the other hand, the     allowance of narrower claims may limit the value of our <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>The laws of some <font color="blue">foreign countries</font> do not protect <font color="blue"><font color="blue">proprietary</font> rights</font> to the     same  extent as the laws of the <font color="blue">United States</font>, and many companies have     <font color="blue">encountered</font> <font color="blue">significant</font> problems and costs in protecting their <font color="blue">proprietary</font>     rights in these <font color="blue">foreign countries</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">could become involved</font> in <font color="blue">infringement actions</font> to enforce and/or protect     our patents</td>
    </tr>
    <tr>
      <td><font color="blue">Regardless </font>of the outcome, patent <font color="blue">litigation</font> is expensive and     time consuming and <font color="blue">would distract</font> our <font color="blue"><font color="blue">management</font> from</font> other <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Some of our <font color="blue"><font color="blue">competitors</font> may</font> be able to sustain the costs of complex patent     <font color="blue">litigation</font> more <font color="blue">effectively</font> than we could because they have <font color="blue">substantially</font>     greater  resources</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties  </font>resulting from the <font color="blue">initiation</font> and     <font color="blue">continuation</font> of any patent <font color="blue">litigation</font> <font color="blue">could limit</font> our ability to continue     our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">technology</font> infringes the <font color="blue"><font color="blue">intellectual</font> property</font> of our <font color="blue">competitors</font> or     other <font color="blue">third parties</font>, we may be required to <font color="blue">pay license fees</font> or damages</td>
    </tr>
    <tr>
      <td>If any relevant claims of third-party patents that are adverse to us are     upheld as valid and enforceable, we could be prevented from <font color="blue">commercializing</font>     our <font color="blue">technology</font> or could be required to obtain licenses from the owners of     such patents</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">such licenses would</font> be available     or,  if available, would be on acceptable terms</td>
    </tr>
    <tr>
      <td>Some <font color="blue">licenses may</font> be     non-exclusive and, therefore, our <font color="blue"><font color="blue">competitors</font> may</font> have access to the same     <font color="blue">technology</font> licensed to us</td>
    </tr>
    <tr>
      <td>In addition, if any parties <font color="blue">successfully</font> claim     that the creation or use of our <font color="blue">technology</font> infringes upon their <font color="blue">intellectual</font>     <font color="blue">property rights</font>, we may be forced to pay damages, including <font color="blue">treble damages</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">security measures may</font> not <font color="blue">adequately protect</font> our unpatented <font color="blue">technology</font>     and, if we are unable to protect the <font color="blue"><font color="blue">confidential</font>ity</font> of our <font color="blue">proprietary</font>     information and know-how, the value of our <font color="blue">technology</font> may be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>Our success <font color="blue">depends upon</font> know-how, unpatentable <font color="blue">trade secrets</font>, and the     skills, knowledge and experience of our scientific and <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>As  a  result,  we require all employees to agree to a <font color="blue"><font color="blue">confidential</font>ity</font>     provision that prohibits the <font color="blue">disclosure</font> of <font color="blue">confidential</font> information to     anyone  outside  of  our  company,  during  the term of <font color="blue">employment</font> and     thereafter</td>
    </tr>
    <tr>
      <td>We also require all employees to disclose and assign to us the     rights to their ideas, <font color="blue">development</font>s, <font color="blue">discoveries</font> and <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>We also     attempt to <font color="blue">enter into</font> similar <font color="blue">agreements</font> with our consultants, advisors and     <font color="blue">research <font color="blue">collaborators</font></font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that <font color="blue">adequate protection</font> for     our  trade  secrets, know-how or other <font color="blue">proprietary</font> information against     <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font> will be available</td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________       We <font color="blue">occasionally provide</font> information to <font color="blue">research <font color="blue">collaborators</font></font> in academic     <font color="blue"><font color="blue">institution</font>s</font> and request the <font color="blue">collaborators</font> to <font color="blue">conduct certain tests</font></td>
    </tr>
    <tr>
      <td>We     cannot  assure  you  that  the  academic  <font color="blue"><font color="blue">institution</font>s</font> will not assert     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> in the results of the <font color="blue">tests conducted by</font> the     research  <font color="blue">collaborators</font>,  or that the academic <font color="blue"><font color="blue">institution</font>s</font> will grant     licenses under such <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> to us on acceptable terms,     if at all</td>
    </tr>
    <tr>
      <td>If the assertion of <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> by an academic     <font color="blue">institution</font> is <font color="blue">substantiated</font>, and the academic <font color="blue">institution</font> does not grant     <font color="blue"><font color="blue"><font color="blue">intellectual</font> property</font> rights</font> to us, these <font color="blue">events <font color="blue">could limit</font></font> our ability to     <font color="blue">commercialize</font> our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>As  we  evolve  from  a <font color="blue">company primarily involved</font> in the research and     <font color="blue">development</font>  of  our  <font color="blue">technology</font> into one that is <font color="blue">also involved</font> in the     <font color="blue">commercialization</font> of our <font color="blue">technology</font>, we may have <font color="blue"><font color="blue">difficult</font>y managing</font> our     growth and expanding our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>As  our  business  grows, we may need to <font color="blue">add employees</font> and enhance our     <font color="blue">management</font>, systems and procedures</td>
    </tr>
    <tr>
      <td>We will need to <font color="blue">successfully</font> integrate     our internal <font color="blue">operations</font> with the <font color="blue">operations</font> of our <font color="blue">marketing partners</font>,     manufacturers, distributors and suppliers to produce and market <font color="blue">commercially</font>     <font color="blue">viable products</font></td>
    </tr>
    <tr>
      <td>We may also need to <font color="blue">manage additional relationships with</font>     various collaborative partners, suppliers and other <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>we do not <font color="blue">presently conduct research</font> and <font color="blue">development</font> <font color="blue">activities</font> in-house, we     may undertake those <font color="blue">activities</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Expanding </font>our business will     place a <font color="blue">significant</font> burden on our <font color="blue">management</font> and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may not be     able to implement <font color="blue">improvements</font> to our <font color="blue">management</font> information and control     systems in an <font color="blue">efficient</font> and <font color="blue">timely manner</font> and we <font color="blue">may discover deficiencies</font>     in our <font color="blue">existing systems</font> and controls</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">effectively</font> respond to     changes may make it <font color="blue">difficult</font> for us to manage our growth and expand our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have no marketing or <font color="blue">sales history</font> and <font color="blue">depend on</font> third-party marketing     partners</td>
    </tr>
    <tr>
      <td>Any failure of these parties to perform would delay or limit our     <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>We have no history of marketing, distributing or selling bio<font color="blue">technology</font>     products  and  we are <font color="blue">relying on</font> our ability to <font color="blue">successfully</font> establish     <font color="blue">marketing partners</font> or other <font color="blue">arrangements</font> with <font color="blue">third parties</font> to market,     distribute and sell a <font color="blue"><font color="blue">commercially</font> viable</font> product both here and abroad</td>
    </tr>
    <tr>
      <td>Our     business plan also envisions creating <font color="blue">strategic alliances</font> to access needed     <font color="blue">commercialization</font> and <font color="blue">marketing expertise</font></td>
    </tr>
    <tr>
      <td>We may not be able to attract     qualified sub-licensees, distributors or <font color="blue">marketing partners</font>, and even if     qualified, these <font color="blue">marketing partners</font> may not be able to <font color="blue">successfully</font> market     <font color="blue">agricultural</font>  products or <font color="blue"><font color="blue">human health</font> <font color="blue"><font color="blue">application</font>s</font></font> developed with our     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">successfully</font> establish <font color="blue">distribution</font> channels, or     if our <font color="blue">marketing partners</font> fail to <font color="blue">provide adequate levels</font> of sales, our     <font color="blue">commercialization</font> efforts will be delayed or limited and we will not be able     to <font color="blue">generate revenue</font></td>
    </tr>
    <tr>
      <td>We will <font color="blue">depend on</font> <font color="blue"><font color="blue">joint venture</font>s</font> and <font color="blue">strategic alliances</font> to develop and     market our <font color="blue">technology</font> and, if these <font color="blue">arrangements</font> are not successful, our     <font color="blue">technology</font>  may not be developed and the expenses to <font color="blue">commercialize</font> our     <font color="blue">technology</font> will increase</td>
    </tr>
    <tr>
      <td>In its current state of <font color="blue">development</font>, our <font color="blue">technology</font> is not ready to be     marketed   to   consumers</td>
    </tr>
    <tr>
      <td>We  intend  to  follow  a  multi-faceted     <font color="blue">commercialization</font> strategy that involves the licensing of our <font color="blue">technology</font> to     business partners for the purpose of further technological <font color="blue">development</font>,     marketing and <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>We are seeking business partners who will share     the burden of our <font color="blue"><font color="blue">development</font> costs</font> while our <font color="blue">technology</font> is still being     developed, and who <font color="blue">will pay us royalties</font> when they market and distribute     <font color="blue">products incorporating</font> our <font color="blue">technology</font> upon       21     ______________________________________________________________________       <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">establishment</font> of <font color="blue"><font color="blue">joint venture</font>s</font> and strategic     <font color="blue">alliances may</font> create future <font color="blue">competitors</font>, especially in <font color="blue">certain regions</font>     abroad where we do not pursue <font color="blue">patent protection</font></td>
    </tr>
    <tr>
      <td>If we fail to establish     <font color="blue">beneficial</font> business partners and <font color="blue">strategic alliances</font>, our <font color="blue">growth will suffer</font>     and the continued <font color="blue">development</font> of our <font color="blue">technology</font> may be harmed</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in the <font color="blue">agricultural</font> and <font color="blue">human health</font> bio<font color="blue">technology</font> industries is     intense and <font color="blue">technology</font> is changing rapidly</td>
    </tr>
    <tr>
      <td>If our <font color="blue">competitors</font> market their     <font color="blue">technology</font> faster than we do, we may not be able to <font color="blue">generate revenue</font>s from     the <font color="blue">commercialization</font> of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">agricultural</font> and <font color="blue">human health</font> bio<font color="blue">technology</font> companies are engaged in     research and <font color="blue">development</font> <font color="blue">activities</font> relating to senescence and apoptosis</td>
    </tr>
    <tr>
      <td>The market for <font color="blue">plant protection</font> and <font color="blue">yield enhancement products</font> is intensely     competitive, rapidly changing and <font color="blue">undergoing consolidation</font></td>
    </tr>
    <tr>
      <td>We may be     unable to compete <font color="blue">successfully</font> against our current and future <font color="blue">competitors</font>,     which may result in price reductions, reduced margins and the <font color="blue">inability</font> to     achieve <font color="blue">market <font color="blue">acceptance</font></font> for <font color="blue">products containing</font> our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue">competitors</font> in the field of plant senescence gene <font color="blue">technology</font> are companies     that develop and produce <font color="blue">transgenic plants</font> and include <font color="blue">major international</font>     <font color="blue">agricultural</font> companies, specialized bio<font color="blue">technology</font> companies, research and     academic <font color="blue"><font color="blue">institution</font>s</font> and, <font color="blue">potentially</font>, our <font color="blue">joint venture</font> and strategic     <font color="blue">alliance partners</font></td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">competitors</font> that are involved in apoptosis research     include:   Amgen;  Centocor;  Genzyme; OSI Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>; and     Vertex Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>Many of these <font color="blue">competitors</font> have <font color="blue">substantially</font>     greater financial, marketing, sales, <font color="blue">distribution</font> and technical resources     than us and have more experience in research and <font color="blue">development</font>, clinical     trials, <font color="blue">regulatory</font> matters, <font color="blue">manufacturing</font> and marketing</td>
    </tr>
    <tr>
      <td>We anticipate     <font color="blue">increased competition</font> in the <font color="blue">future as new companies enter</font> the market and     new <font color="blue">technologies</font> become available</td>
    </tr>
    <tr>
      <td>Our <font color="blue">technology</font> may be rendered obsolete     or <font color="blue">uneconomical by technological advances</font> or <font color="blue">entirely different approaches</font>     developed by one or more of our <font color="blue">competitors</font>, which will prevent or limit our     ability to <font color="blue">generate revenue</font>s from the <font color="blue">commercialization</font> of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our business is subject to <font color="blue">various <font color="blue">government</font> <font color="blue">regulations</font></font> and, if we are     unable to obtain <font color="blue">regulatory</font> approval, we may not be able to continue our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>At present, the US <font color="blue">federal <font color="blue">government</font> regulation</font> of bio<font color="blue">technology</font> is     <font color="blue">divided among three agencies</font>:       ·          the USDA regulates the import, field testing and interstate     movement of <font color="blue">specific types</font> of <font color="blue">genetic <font color="blue">engineering</font></font> that may be used in the     creation of <font color="blue">transgenic plants</font>;       ·         the EPA <font color="blue">regulates activity</font> related to the invention of plant     pesticides and herbicides, which may include <font color="blue">certain kinds</font> of transgenic     plants; and       ·         the FDA <font color="blue">regulates foods derived from new plant varieties</font></td>
    </tr>
    <tr>
      <td>The FDA requires that <font color="blue">transgenic plants</font> meet the <font color="blue">same standards</font> for safety     that are required for all other plants and foods in general</td>
    </tr>
    <tr>
      <td>Except in the     case of <font color="blue">additives</font> that <font color="blue"><font color="blue">significant</font>ly</font> alter a food’s structure, the FDA does     not require any <font color="blue">additional standards</font> or <font color="blue">specific approval</font> for <font color="blue">genetically</font>     engineered foods, but expects <font color="blue">transgenic plant developers</font> to consult the FDA     before introducing a <font color="blue">new food into</font> the marketplace</td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________       Use of our <font color="blue">technology</font>, if developed for <font color="blue"><font color="blue">human health</font> <font color="blue"><font color="blue">application</font>s</font></font>, will also     be subject to FDA regulation</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">must approve</font> any drug or biologic     product before it can be marketed in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In addition, prior     to  being  sold  outside  of the US, any products resulting from the     <font color="blue">application</font>  of  our  human  health <font color="blue">technology</font> must be approved by the     <font color="blue">regulatory</font> agencies of foreign <font color="blue"><font color="blue">government</font>s</font></td>
    </tr>
    <tr>
      <td>Prior to filing a new drug     <font color="blue">application</font> or biologics license <font color="blue">application</font> with the FDA, we would have to     perform extensive <font color="blue">clinical trials</font>, and prior to beginning any clinical     trial, we need to perform extensive <font color="blue">preclinical testing which could</font> take     <font color="blue">several years</font> and may require substantial <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>We believe that our current <font color="blue">activities</font>, which to date have <font color="blue">been confined</font> to     research and <font color="blue">development</font> efforts, do not require licensing or <font color="blue">approval by</font>     any <font color="blue"><font color="blue">government</font>al</font> <font color="blue">regulatory</font> agency</td>
    </tr>
    <tr>
      <td>However, federal, state and foreign     <font color="blue">regulations</font>  relating  to  crop  protection  products and <font color="blue">human health</font>     <font color="blue"><font color="blue">application</font>s</font> developed through bio<font color="blue">technology</font> are subject to <font color="blue">public concerns</font>     and <font color="blue">political circumstances</font>, and, as a result, <font color="blue">regulations</font> have changed and     may change <font color="blue">substantially</font> in the future</td>
    </tr>
    <tr>
      <td>Accordingly, we may become subject     to <font color="blue"><font color="blue">government</font>al</font> <font color="blue">regulations</font> or approvals or become subject to licensing     <font color="blue">requirements</font> in <font color="blue">connection with</font> our research and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>We may     also be required to obtain <font color="blue">such licensing</font> or <font color="blue">approval from</font> the <font color="blue"><font color="blue">government</font>al</font>     <font color="blue">regulatory</font> agencies described above, or from state agencies, prior to the     <font color="blue">commercialization</font> of our <font color="blue">genetically</font> transformed plants and <font color="blue">human health</font>     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">marketing partners</font> who utilize our <font color="blue">technology</font>     or <font color="blue">sell products grown with</font> our <font color="blue">technology</font> may be subject to <font color="blue">government</font>     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>If unfavorable <font color="blue"><font color="blue">government</font>al</font> <font color="blue">regulations</font> are <font color="blue">imposed on</font> our     <font color="blue">technology</font> or if we fail to obtain licenses or approvals in a <font color="blue">timely manner</font>,     we may not be able to continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical </font>studies and <font color="blue">clinical trials</font> of our <font color="blue"><font color="blue">human health</font> <font color="blue"><font color="blue">application</font>s</font></font> may     be <font color="blue">unsuccessful</font>, which could delay or prevent <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical </font> studies  may  reveal  that our <font color="blue">human health</font> <font color="blue">technology</font> is     <font color="blue">ineffective</font>  or harmful, and/or <font color="blue">clinical trials</font> may be <font color="blue">unsuccessful</font> in     <font color="blue">demonstrating efficacy</font> and safety of our <font color="blue">human health</font> <font color="blue">technology</font>, which     would <font color="blue"><font color="blue">significant</font>ly</font> limit the <font color="blue">possibility</font> of obtaining <font color="blue">regulatory</font> approval     for any drug or <font color="blue">biologic product manufactured with</font> our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">The FDA     </font>requires submission of extensive preclinical, clinical and <font color="blue">manufacturing</font>     data to assess the efficacy and safety of <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>Furthermore,     the success of <font color="blue">preliminary studies</font> does not ensure commercial success, and     later-stage  clinical  trials  may  fail to confirm the results of the     <font color="blue">preliminary studies</font></td>
    </tr>
    <tr>
      <td>Even if we receive <font color="blue">regulatory</font> approval, consumers may not <font color="blue">accept products</font>     containing our <font color="blue">technology</font>, which will prevent us from being <font color="blue">profitable since</font>     we have no other source of revenue</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot guarantee</font> that consumers will accept <font color="blue">products containing</font> our     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Recently, there has <font color="blue">been consumer</font> concern and <font color="blue">consumer advocate</font>     <font color="blue">activism with respect</font> to <font color="blue">genetically</font> engineered consumer products</td>
    </tr>
    <tr>
      <td>The     <font color="blue">adverse consequences from heightened consumer</font> concern in this regard could     affect the markets for products developed with our <font color="blue">technology</font> and <font color="blue">could also</font>     result in increased <font color="blue">government</font> regulation in response to that concern</td>
    </tr>
    <tr>
      <td>If     the public or potential customers perceive our <font color="blue">technology</font> to be genetic     <font color="blue">modification</font> or <font color="blue">genetic <font color="blue">engineering</font></font>, <font color="blue">agricultural</font> products grown with our     <font color="blue">technology</font> may not gain <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________       We <font color="blue">depend on</font> our <font color="blue">key personnel</font> and, if we are not able to attract and retain     <font color="blue">qualified scientific</font> and business personnel, we may not be able to grow our     business or develop and <font color="blue">commercialize</font> our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We  are  highly  <font color="blue">dependent on</font> our scientific advisors, consultants and     third-party research partners</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will also depend</font> in part on the     <font color="blue">continued service</font> of our <font color="blue">key employees</font> and our ability to identify, hire and     retain <font color="blue">additional qualified personnel</font> in an <font color="blue">intensely competitive market</font></td>
    </tr>
    <tr>
      <td>Although we have <font color="blue">employment</font> <font color="blue">agreements</font> with all of our <font color="blue">key employees</font> and a     <font color="blue">research agreement with</font> Dr</td>
    </tr>
    <tr>
      <td>Thompson, these <font color="blue">agreements</font> may be terminated     upon short or no notice</td>
    </tr>
    <tr>
      <td>We do not maintain key person <font color="blue">life insurance on</font>     any member of <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>The failure to attract and retain <font color="blue">key personnel</font>     <font color="blue">could limit</font> our growth and hinder our research and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>Certain provisions of our charter, by-laws and <font color="blue">Delaware </font>law could make a     takeover <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>Certain provisions of our <font color="blue">certificate</font> of <font color="blue">in<font color="blue">corporation</font></font> and by-laws could     make it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire control of us, even if     the change in <font color="blue">control would</font> be <font color="blue">beneficial</font> to <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font>     of  <font color="blue">in<font color="blue">corporation</font></font>  <font color="blue">authorizes</font> our board of <font color="blue">directors</font> to issue, without     <font color="blue">stockholder approval</font>, except as may be required by the rules of the American     Stock Exchange, 5cmam000cmam000 shares of preferred stock with voting, conversion     and other rights and <font color="blue">preferences</font> that could <font color="blue">adversely</font> affect the voting     power or other rights of the holders of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Similarly, our     by-laws do not restrict our board of <font color="blue">directors</font> from issuing preferred stock     without <font color="blue">stockholder approval</font></td>
    </tr>
    <tr>
      <td>In addition, we are subject to the Business Combination Act of the <font color="blue">Delaware </font>    General Corporation Law which, subject to certain <font color="blue">exceptions</font>, restricts     <font color="blue">certain <font color="blue">transactions</font></font> and business <font color="blue">combinations</font> between a <font color="blue">corporation</font> and a     stockholder owning 15prca or more of the <font color="blue">corporation</font>’s outstanding voting stock     for a period of <font color="blue">three years from</font> the <font color="blue">date such stockholder becomes</font> a 15prca     owner</td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions may</font> have the effect of delaying or preventing a     change of control of <font color="blue">us without action by</font> our <font color="blue">stockholders</font> and, therefore,     could <font color="blue">adversely</font> affect the value of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Furthermore,  in the event of our merger or <font color="blue">consolidation with</font> or into     another <font color="blue">corporation</font>, or the sale of all or <font color="blue">substantially</font> all of our assets     in which the successor <font color="blue">corporation</font> does not assume <font color="blue">outstanding options</font> or     issue equivalent options, our board of <font color="blue">directors</font> is required to provide     <font color="blue">accelerated vesting</font> of <font color="blue">outstanding options</font></td>
    </tr>
    <tr>
      <td><font color="blue">Increasing </font>political and <font color="blue">social turmoil</font>, such as terrorist and military     actions,  increase the <font color="blue">difficult</font>y for us and our <font color="blue">strategic partners</font> to     <font color="blue">forecast accurately</font> and plan future business <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Recent political and <font color="blue">social turmoil</font>, including the conflict in Iraq and the     <font color="blue">current crisis</font> in the Middle East, can be expected to <font color="blue">put further pressure</font>     <font color="blue">on economic conditions</font> in the <font color="blue"><font color="blue">United States</font> </font>and worldwide</td>
    </tr>
    <tr>
      <td>These political,     social and <font color="blue">economic conditions may</font> make it <font color="blue">difficult</font> for us to plan future     business <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Specifically, if the current situation in <font color="blue">Israel     </font>continues to escalate, our <font color="blue">joint venture</font> with Rahan Meristem Ltd</td>
    </tr>
    <tr>
      <td>could be     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________       Risks Related to Our <font color="blue">Common Stock </font>      Our <font color="blue">management</font> and other <font color="blue">affiliates</font> have <font color="blue">significant</font> control of our common     stock  and  could <font color="blue"><font color="blue">significant</font>ly</font> influence our actions in a manner that     <font color="blue">conflicts with</font> our interests and the interests of other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>As  of June 30, 2006, our executive officers, <font color="blue">directors</font> and <font color="blue">affiliated</font>     entities together <font color="blue">beneficial</font>ly own approximately 41dtta4prca of the outstanding     shares of our <font color="blue">common stock</font>, assuming the exercise of options and warrants     which are <font color="blue">currently exercisable</font> or will become exercisable within 60 days of     June 30, 2006, held by these <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of October </font>11, 2006, upon the     closing  of  our <font color="blue">private placement</font> of <font color="blue">equity securities</font>, our executive     officers, <font color="blue">directors</font>, and <font color="blue">affiliated</font> entities together <font color="blue">beneficial</font>ly own     approximately 37dtta2prca of the <font color="blue">Outstanding </font>shares of our <font color="blue">common stock</font>, assuming     the exercise of options and <font color="blue">warrants which</font> are <font color="blue">currently exercisable</font> or will     become  exercisable  within 60 days of October 11, 2006, held by these     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>As a result, these <font color="blue">stockholders</font>, acting together, will be     able to exercise <font color="blue">significant</font> influence over matters requiring <font color="blue">approval by</font>     our <font color="blue">stockholders</font>, including the election of <font color="blue">directors</font>, and may not always     act in the <font color="blue">best interests</font> of other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>Such a <font color="blue">concentration</font> of     ownership may have the effect of delaying or preventing a change in control     of us, including <font color="blue">transactions</font> in which our <font color="blue">stockholders</font> might otherwise     receive a premium for their shares over then current <font color="blue">market price</font>s</td>
    </tr>
    <tr>
      <td>Our <font color="blue">stockholders</font> may experience substantial <font color="blue">dilution as</font> a result of the     exercise of <font color="blue">outstanding options</font> and warrants to purchase our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of June </font>30, 2006, we have <font color="blue">granted options outside</font> of our <font color="blue">stock option</font>     plan to purchase 10cmam000 shares of our <font color="blue">common stock</font> and <font color="blue">outstanding warrants</font>     to purchase 5cmam860cmam091 shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, as of <font color="blue">June     </font>30, 2006, we have reserved 3cmam000cmam000 shares of our <font color="blue">common stock</font> for issuance     upon the exercise of <font color="blue">options granted pursuant</font> to our <font color="blue">stock option</font> plan,     2cmam516cmam500 of which have been granted, 90cmam000 of which have <font color="blue">been exercised</font>,     2cmam426cmam500 of which are outstanding, and 483cmam500 of which may be granted in     the  future</td>
    </tr>
    <tr>
      <td><font color="blue">As of October </font>11, 2006, upon the closing of our private     placement of <font color="blue">equity securities</font>, we have <font color="blue">outstanding warrants</font> to purchase     6cmam982cmam285 shares of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The exercise of these options and     <font color="blue">warrants will</font> result in dilution to our <font color="blue">existing <font color="blue">stockholders</font></font> and could have     a material adverse effect on our stock price</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our total outstanding shares of <font color="blue">common stock</font> may be     sold in the market in the near future, which could cause the <font color="blue">market price</font> of     our <font color="blue">common stock</font> to drop <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of June </font>30, 2006, we had 15cmam477cmam388 shares of our <font color="blue">common stock</font> issued and     outstanding, of which approximately 1cmam595cmam651 shares are <font color="blue">registered pursuant</font>     to a <font color="blue"><font color="blue">registration statement</font> on</font> Form S-3, which was declared <font color="blue">effective on</font>     June 17, 2005, and the remainder of which are <font color="blue">either eligible</font> to be sold     under  SEC  Rule 144 or are in the <font color="blue">public float</font></td>
    </tr>
    <tr>
      <td>In addition, we have     registered 965cmam380 shares of our <font color="blue">Common Stock </font><font color="blue">underlying warrants previously</font>     issued on the Form S-3 <font color="blue">registration statement</font> that was declared <font color="blue">effective on</font>     June  17, 2005, and we registered 3cmam000cmam000 shares of our <font color="blue">common stock</font>     <font color="blue">underlying options granted</font> or to be <font color="blue">granted under</font> our <font color="blue">stock option</font> plan</td>
    </tr>
    <tr>
      <td>As     of October 11, 2006, upon the closing of our <font color="blue">private placement</font> of equity     securities,  we  had  17cmam473cmam694 shares of our <font color="blue">common stock</font> issued and     outstanding</td>
    </tr>
    <tr>
      <td>Consequently, sales of substantial amounts of our <font color="blue">common stock</font>     in the <font color="blue">public market</font>, or the <font color="blue">perception</font> that <font color="blue">such sales could</font> occur, may     have a material adverse effect on our stock price</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">common stock</font> has a limited trading market, which <font color="blue">could limit</font> your     ability to resell your shares of <font color="blue">common stock</font> at or above your purchase     price</td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> is quoted on the <font color="blue"><font color="blue">American Stock Exchange</font> </font>and currently has     a limited trading market</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">American Stock Exchange</font> </font>requires us to meet     minimum financial <font color="blue">requirements</font> in order to maintain our listing</td>
    </tr>
    <tr>
      <td>Currently,     we believe that we meet the continued listing <font color="blue">requirements</font> of the American     Stock Exchange</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that an <font color="blue">active trading market will</font>     develop or, if developed, will       25     ______________________________________________________________________       be maintained</td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue">stockholders</font> may find it <font color="blue">difficult</font> to     dispose of shares of our <font color="blue">common stock</font> and, as a result, may suffer a loss of     all or a substantial portion of their <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">common stock</font> is <font color="blue">delisted from</font> the <font color="blue">American Stock Exchange</font>, we may not     be able to list on any other <font color="blue">stock exchange</font>, and our <font color="blue">common stock</font> may be     subject to the “<font color="blue">penny stock</font>” <font color="blue">regulations</font> which may affect the ability of our     <font color="blue">stockholders</font> to sell their shares</td>
    </tr>
    <tr>
      <td>The  American  Stock  Exchange  requires  us to <font color="blue">meet minimum financial</font>     <font color="blue">requirements</font> in order to maintain our listing</td>
    </tr>
    <tr>
      <td>Currently, we believe that     we meet the continued listing <font color="blue">requirements</font> of the <font color="blue">American Stock Exchange</font></td>
    </tr>
    <tr>
      <td>If we do not continue to meet the continued listing <font color="blue">requirements</font>, we could     be delisted</td>
    </tr>
    <tr>
      <td>If we are <font color="blue">delisted from</font> the <font color="blue">American Stock Exchange</font>, our     <font color="blue">common stock</font> likely will become a “<font color="blue">penny stock</font></td>
    </tr>
    <tr>
      <td>”  In general, <font color="blue">regulations</font> of     the SEC define a “<font color="blue">penny stock</font>” to be an <font color="blue">equity security</font> that is not listed     on a <font color="blue">national securities exchange</font> or the <font color="blue">NASDAQ Stock Market </font>and that has a     <font color="blue">market price</font> of less than dlra5dtta00 per share or with an exercise price of less     than dlra5dtta00 per share, subject to certain <font color="blue">exceptions</font></td>
    </tr>
    <tr>
      <td>If our <font color="blue">common stock</font>     becomes a <font color="blue">penny stock</font>, additional sales practice <font color="blue">requirements</font> would be     <font color="blue">imposed on</font> broker-dealers that <font color="blue">sell such securities</font> to persons other than     <font color="blue">certain qualified investors</font></td>
    </tr>
    <tr>
      <td>For <font color="blue">transactions</font> involving a <font color="blue">penny stock</font>,     <font color="blue">unless exempt</font>, a broker-dealer must make a <font color="blue">special suitability determination</font>     for  the  purchaser and receive the purchaser’s written consent to the     <font color="blue">transaction prior</font> to the sale</td>
    </tr>
    <tr>
      <td>In addition, the rules on <font color="blue">penny stock</font>s     require  delivery,  prior to and after any <font color="blue">penny stock</font> transaction, of     <font color="blue">disclosure</font>s required by the SEC       If our <font color="blue">common stock</font> were subject to the rules on <font color="blue">penny stock</font>s, the market     liquidity for our <font color="blue">common stock</font> could be severely and <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Accordingly, the ability of holders of our <font color="blue">common stock</font> to sell their shares     in the <font color="blue">secondary market may also</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> may fluctuate and may drop below the     price you paid</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that you will be able to resell the shares of our     <font color="blue">common stock</font> at or above your <font color="blue">purchase price</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our     <font color="blue">common stock</font> may fluctuate <font color="blue"><font color="blue">significant</font>ly</font> in response to a number of factors,     some of which are beyond our control</td>
    </tr>
    <tr>
      <td>These factors include:       ·                  <font color="blue">quarterly variations</font> in operating results;       ·                  the progress or perceived progress of our research and     <font color="blue">development</font> efforts;       ·                  changes in <font color="blue">accounting treatments</font> or principles;       ·                  <font color="blue">announcements by us</font> or our <font color="blue">competitors</font> of new <font color="blue">technology</font>,     product  and service offerings, <font color="blue">significant</font> contracts, acquisitions or     <font color="blue">strategic relationships</font>;       ·                  <font color="blue">additions</font> or <font color="blue">departures</font> of <font color="blue">key personnel</font>;       ·                  <font color="blue">future offerings</font> or resales of our <font color="blue">common stock</font> or other     securities;       ·                   stock  market  price  and  volume  <font color="blue">fluctuations</font> of     publicly-traded  companies  in  general  and  <font color="blue">development</font> companies in     particular; and       ·      general political, economic and <font color="blue">market conditions</font></td>
    </tr>
    <tr>
      <td>Because we do not intend to pay, and have not paid, any <font color="blue"><font color="blue">cash dividends</font> on</font>     our shares of <font color="blue">common stock</font>, our <font color="blue">stockholders</font> will not be able to receive a     return on their <font color="blue">shares unless</font> the value of our <font color="blue">common stock</font> appreciates and     they sell their shares</td>
    </tr>
    <tr>
      <td>We have never paid or declared any <font color="blue"><font color="blue">cash dividends</font> on</font> our <font color="blue">common stock</font> and we     intend  to  retain  any <font color="blue">future earnings</font> to finance the <font color="blue">development</font> and     expansion of our business</td>
    </tr>
    <tr>
      <td>We do not anticipate paying any <font color="blue">cash dividends</font>     on our <font color="blue">common stock</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Therefore, our <font color="blue">stockholders</font>     will not be able to receive a return on their <font color="blue">investment</font> unless the value of     our <font color="blue">common stock</font> appreciates and they sell their shares</td>
    </tr>
  </tbody>
</table>